Innate Pharma (IPHA) Non-Current Deferred Tax Liability (2018 - 2024)

Innate Pharma has reported Non-Current Deferred Tax Liability for 7 years, with the latest figure at $9.8 million in Q2 2024.

• For the quarter ending Q2 2024, Non-Current Deferred Tax Liability fell 6.74% year-over-year to $9.8 million; the trailing twelve-month figure through Jun 2024 stood at $9.8 million (down 6.74% YoY), and the FY2023 full-year result was $9.7 million, up 10.85% from the prior year.
• Non-Current Deferred Tax Liability for Q2 2024 stood at $9.8 million, up from $9.7 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $1.3 billion in Q2 2020, with the low at $5.8 million in Q4 2021.
• Historically, Non-Current Deferred Tax Liability has averaged $148.5 million across 5 years, with a median of $8.7 million in 2022.
• Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability soared 493.61% — and 2021, when it slumped 99.49%.
• Innate Pharma's Non-Current Deferred Tax Liability stood at $8.4 million in 2020, then sank by 31.93% to $5.8 million in 2021, then surged by 51.98% to $8.7 million in 2022, then grew by 10.85% to $9.7 million in 2023, then increased by 1.39% to $9.8 million in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $9.8 million (Q2 2024), $9.7 million (Q4 2023), and $10.5 million (Q2 2023), per Business Quant data.